期刊文献+

重组人骨保护素片段OPG^(179)与人血清白蛋白在毕赤酵母中的融合表达 被引量:4

Expression of the rhOPG^(179)-HSA Fusion Protein in Pichia pastoris
在线阅读 下载PDF
导出
摘要 目的:在毕赤酵母中融合表达人骨保护素(OPG)片段OPG179与人血清白蛋白(HSA)。方法:通过RT-PCR扩增获得OPG179基因,构建表达质粒pHILD2-rhOPG179-HSA,转化至毕赤酵母菌中进行表达、纯化,对分泌表达产物进行SDS-PAGE及Western印迹检测。结果:酶切鉴定与测序结果显示重组表达质粒pHILD2-rhOPG179-HSA正确;经Western印迹检测,融合蛋白rhOPG179-HSA的相对分子质量约为97×103,符合预期值;rhHSA-OPG179在毕赤酵母中的表达量约为80 mg/L。结论:表达并纯化制备了重组骨保护素片段与人血清白蛋白的融合蛋白,为后续的生物学活性研究奠定了一定的基础。 Objective:To express in Pichia pastoris and purify recombinant human osteoprogerin(OPG) fragment OPG^179 and human serum albumin(HSA) fusion protein.Methods:The gene of OPG^179 was amplified by RT-PCR.The plasmid of pHILD2-rhOPG^179-HSA was constructed and then transformed to Pichia pastoris.The rhOPG^179-HSA fusion protein was expressed,purified,and analyzed with SDS-PAGE and Western blot.Results:The expression plasmid of pHILD2-rhOPG^179-HSA was proved correct after the plasmid was identified and sequenced.The molecular mass of fusion protein was about 97 kD.The rhOPG^179-HSA fusion protein was expressed and purified successfully from Pichia pastoris with relative higher-efficient expression level(about 80 mg/L).Conclusion:The secreted recombinant fusion protein rhOPG^179-HSA has been successfully expressed and purified,and supply for a foundation for its biological activity analysis
出处 《生物技术通讯》 CAS 2011年第1期15-18,23,共5页 Letters in Biotechnology
基金 总装后司令部及卫生局项目(07ZH10) 306医院院级课题(07QN10)
关键词 人骨保护素 人血清白蛋白 融合蛋白 毕赤酵母 表达 纯化 recombinant human osteoprogerin human serum albumin fusion protein Pichia pastoris expression purification
  • 相关文献

参考文献4

二级参考文献63

  • 1黄鹏,王岩,迟志永,杨子义,倪健,杨武剑,王冉东,白金柱.联合应用重组人骨保护素和阿伦膦酸钠抑制成熟破骨细胞的体外实验研究[J].中华外科杂志,2005,43(12):812-816. 被引量:14
  • 2唱韶红,巩新,杨志愉,王同映,马国昌,马清钧,吴军.人血清白蛋白和人干扰素α2b的融合蛋白在毕赤酵母中的表达[J].生物工程学报,2006,22(2):173-179. 被引量:16
  • 3Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation on bone density[J].Cell,1997,89(2):309-319.
  • 4Kadri A,Ea HK,Bazille C,et al.Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis[J].Arthritis Rheum,2008,58 (8):2379-2386.
  • 5McClung MR.Inhibition of RANKL as a treatment for osteoporosis:preclinical and early clinical studies[J].Curr Osteoporos Rep,2006,4(1):28-33.
  • 6Tunyogi-Csapo M,Kis-Toth K,Radacs M,et al.Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts:fibroblast-mediated pathologic bone resorption[J].Arthritis Rheum,2008,58(8):2397-2408.
  • 7Haynes D,Crotti T,Weedon H,et al.Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease modifying antirheumatic drug treatment and correlation with radiologic outcome[J].Arthritis Rheum,2008,59(7):911-920.
  • 8Wittrant Y,Theoleyre S,Couillaud S,et al.Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand and osteoprotegerin biological activities[J].Exp Cell Res,2004,293(2):292-301.
  • 9Rucci N,Rufo A,Alamanou M,et al.Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio[J].J Cell Biochem,2007,100(2):464-473.
  • 10Body JJ,Greipp P,Coleman RE,et al.A phase Ⅰ study of AMGN-0007,a recombinant osteoprotegerin construct,in patients with multiple myeloma or breast carcinoma related bone metastases[J].Cancer,2003,97(Suppl 3):887-892.

共引文献46

同被引文献109

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部